PFIZER INC (PFE.DE) Stock Price & Overview

FRA:PFE • US7170811035

23.555 EUR
+0.07 (+0.3%)
Last: Mar 12, 2026, 09:48 AM

The current stock price of PFE.DE is 23.555 EUR. Today PFE.DE is up by 0.3%. In the past month the price increased by 0.19%. In the past year, price decreased by -0.55%.

PFE.DE Key Statistics

52-Week Range18.57 - 24.39
Current PFE.DE stock price positioned within its 52-week range.
1-Month Range22.4 - 23.65
Current PFE.DE stock price positioned within its 1-month range.
Market Cap
133.94B
P/E
8.44
Fwd P/E
9.14
EPS (TTM)
2.79
Dividend Yield
6.46%

PFE.DE Stock Performance

Today
+0.3%
1 Week
+2.96%
1 Month
+0.19%
3 Months
+6.19%
Longer-term
6 Months +12.37%
1 Year -0.55%
2 Years -9.15%
3 Years -36.80%
5 Years -24.05%
10 Years N/A

PFE.DE Stock Chart

PFIZER INC / PFE Daily stock chart

PFE.DE Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to PFE.DE. When comparing the yearly performance of all stocks, PFE.DE turns out to be only a medium performer in the overall market: it outperformed 44.92% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
PFE.DE Full Technical Analysis Report

PFE.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to PFE.DE. There are concerns on the financial health of PFE.DE while its profitability can be described as average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PFE.DE Full Fundamental Analysis Report

PFE.DE Earnings

On February 3, 2026 PFE.DE reported an EPS of 0.66 and a revenue of 17.56B. The company beat EPS expectations (14.29% surprise) and beat revenue expectations (2.56% surprise).

Next Earnings DateApr 27, 2026
Last Earnings DateFeb 3, 2026
PeriodQ4 / 2025
EPS Reported$0.66
Revenue Reported17.557B
EPS Surprise 14.29%
Revenue Surprise 2.56%
PFE.DE Earnings History

PFE.DE Forecast & Estimates

35 analysts have analysed PFE.DE and the average price target is 24.89 EUR. This implies a price increase of 5.66% is expected in the next year compared to the current price of 23.555.

For the next year, analysts expect an EPS growth of -7.56% and a revenue growth -1.41% for PFE.DE


Analysts
Analysts68.57
Price Target24.89 (5.67%)
EPS Next Y-7.56%
Revenue Next Year-1.41%
PFE.DE Forecast & Estimates

PFE.DE Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

PFE.DE Financial Highlights

Over the last trailing twelve months PFE.DE reported a non-GAAP Earnings per Share(EPS) of 2.79. The EPS increased by 3.86% compared to the year before.


Income Statements
Revenue(TTM)62.58B
Net Income(TTM)7.77B
Industry RankSector Rank
PM (TTM) 12.42%
ROA 3.73%
ROE 8.99%
Debt/Equity 0.71
Chartmill High Growth Momentum
EPS Q2Q%4.76%
Sales Q2Q%-1.16%
EPS 1Y (TTM)3.86%
Revenue 1Y (TTM)-1.64%
PFE.DE financials

PFE.DE Ownership

Ownership
Inst Owners67.65%
Shares5.69B
Float5.67B
Ins Owners0.02%
Short Float %N/A
Short RatioN/A
PFE.DE Ownership

About PFE.DE

Company Profile

PFE logo image Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

Company Info

IPO: 1944-01-17

PFIZER INC

66 Hudson Boulevard East

New York City NEW YORK US

Employees: 75000

PFE Company Website

PFE Investor Relations

Phone: 13026587581

PFIZER INC / PFE.DE FAQ

What does PFIZER INC do?

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.


Can you provide the latest stock price for PFIZER INC?

The current stock price of PFE.DE is 23.555 EUR. The price increased by 0.3% in the last trading session.


Does PFE stock pay dividends?

PFIZER INC (PFE.DE) has a dividend yield of 6.46%. The yearly dividend amount is currently 1.49.


What is the ChartMill technical and fundamental rating of PFE stock?

PFE.DE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What is the GICS sector and industry of PFE stock?

PFIZER INC (PFE.DE) operates in the Health Care sector and the Pharmaceuticals industry.


Can you provide the PE ratio for PFE stock?

The PE ratio for PFIZER INC (PFE.DE) is 8.44. This is based on the reported non-GAAP earnings per share of 2.79 and the current share price of 23.555 EUR.


Can you provide the upcoming earnings date for PFIZER INC?

PFIZER INC (PFE.DE) will report earnings on 2026-04-27.